Trial Profile
Engel 2: REal-life aNticoaGulants Comparative bEnefit-risk in Nonvalvular Atrial fibrilLation (NVAF) in France
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Jul 2019
Price :
$35
*
At a glance
- Drugs Apixaban (Primary) ; Dabigatran etexilate (Primary) ; Rivaroxaban (Primary)
- Indications Embolism and thrombosis; Myocardial infarction; Stroke
- Focus Adverse reactions; Therapeutic Use
- Acronyms Engel 2
- Sponsors Boehringer Ingelheim
- 29 Jun 2019 Results assessing the Real-Life Effectiveness and Safety of Dabigatran or Rivaroxaban vs. Vitamin K Antagonists, published in the American Journal of Cardiovascular Drugs
- 12 Nov 2018 New trial record